Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re-analysis of a meta-analysis

被引：0

作者：

Zhou, Shouhao ^{[1
,2
,4
]}

Shen, Chan ^{[1
,2
,3
]}

机构：

[1] Penn State Univ, Coll Med, Dept Publ Hlth Sci, Hershey, PA 17033 USA

[2] Penn State Univ, Penn State Canc Inst, Hershey, PA 17033 USA

[3] Penn State Univ, Coll Med, Dept Surg, Hershey, PA 17033 USA

[4] Penn State Univ, Dept Publ Hlth Sci, 90 Hope Dr,ASB 3400L, Hershey, PA 17033 USA

来源：

JGH OPEN | 2023年 / 7卷 / 02期

关键词：

Bayesian statistics; immune checkpoint inhibitors; meta-analysis; predictive intervals; unresectable hepatocellular carcinoma;

D O I：

10.1002/jgh3.12856

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

We identified analytic limitations in a recent meta-analysis and re-examined the efficacy and safety associated with immune checkpoint inhibitors (ICIs) in unresectable hepatocellular carcinoma (HCC) compared with standard therapies. Our findings mostly contradict conclusions from the previous study, suggesting the need for continuing the investigation of ICIs in HCC with additional clinical evidence.

引用

页码：163 / 164

页数：2

共 50 条

[41] Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis
Gu, Yi-Min
Shang, Qi-Xin
Zhuo, Yue
Zhou, Jian-Feng
Liu, Bo-Wei
Wang, Wen-Ping
Che, Guo-Wei
Chen, Long-Qi
FRONTIERS IN ONCOLOGY, 2021, 11
[42] Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review
Zhang, Ruyi
Wang, Fang
You, Zhiyu
Deng, Dongyang
He, Jiangyan
Yan, Wentao
Quan, Jian
Wang, Jing
Yan, Shujuan
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (02)
[43] Approved immune checkpoint inhibitors in hepatocellular carcinoma: a large-scale meta-analysis and systematic review
Ruyi Zhang
Fang Wang
Zhiyu You
Dongyang Deng
Jiangyan He
Wentao Yan
Jian Quan
Jing Wang
Shujuan Yan
Journal of Cancer Research and Clinical Oncology, 150
[44] Cardiotoxicity associated with immune checkpoint inhibitors: Systematic review and meta-analysis
Piazza, Lavinia
Carollo, Anna
Di Martino, Enrica
Novara, Maria Eugenia
Cutaia, Sofia
Provenzani, Alessio
Rizzo, Sergio
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 206
[45] Cardiovascular adverse events associated with immune checkpoint inhibitors: a meta-analysis
Li, Xi
Li, Dan
FRONTIERS IN IMMUNOLOGY, 2024, 15
[46] A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer
El Helali, Aya
Tao, Jun
Wong, Charlene H. L.
Chan, Wendy Wing-Lok
Mok, Ka-Chun
Wu, Wing Fong
Shitara, Kohei
Mohler, Markus
Boku, Narikazu
Pang, Herbert
Lam, Ka On
FRONTIERS IN ONCOLOGY, 2022, 12
[47] The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
Jingjie Chen
Shengnan Li
Qigu Yao
Nannan Du
Xiaojun Fu
Yuanmei Lou
Mengru Wang
Feiyan Mao
Danyi Mao
Parikshit Asutosh Khadaroo
Yingying Tang
World Journal of Surgical Oncology, 18
[48] Safety and Efficacy of Rechallenge With Immune Checkpoint Inhibitors in Advanced Solid Tumor: A Systematic Review and Meta-Analysis
Xu, Huijun
Yang, Yang
Yan, Ying
Li, Mengge
Wu, Shusheng
Cao, Lulu
Chen, Wenju
Luo, Huiqin
He, Yifu
CANCER MEDICINE, 2024, 13 (20):
[49] The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis
Chen, Jingjie
Li, Shengnan
Yao, Qigu
Du, Nannan
Fu, Xiaojun
Lou, Yuanmei
Wang, Mengru
Mao, Feiyan
Mao, Danyi
Khadaroo, Parikshit Asutosh
Tang, Yingying
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
[50] The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression
Kim, C. M.
Lee, J. B.
Shin, S. J.
Ahn, J. B.
Lee, M.
Kim, H. S.
ESMO OPEN, 2022, 7 (05)

← 1 2 3 4 5 →